Last update 08 May 2025

Telmisartan/Rosuvastatin Calcium/Amlodipine Besylate/Ezetimibe

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
NUVOROZET, 누보로젯정
Target
AT1R x HMGCR x L-type calcium channel x NPC1L1
Action
antagonists, inhibitors, blockers
Mechanism
AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors), L-type calcium channel blockers(Voltage-gated L-type calcium channel blockers)
+ [2]
Therapeutic Areas
Cardiovascular DiseasesEndocrinology and Metabolic Disease
Active Indication
DyslipidemiasEssential HypertensionHypertension+ [1]
Inactive Indication-
Originator Organization
Chong Kun Dang Pharmaceutical Corp.Chong Kun Dang Pharmaceutical Corp.
Active Organization
Chong Kun Dang Pharmaceutical Corp.Chong Kun Dang Pharmaceutical Corp.
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
South Korea (21 Mar 2025),
DyslipidemiasEssential HypertensionHypertension+ [1]
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC26H31ClN2O8S
InChIKeyZPBWCRDSRKPIDG-UHFFFAOYSA-N
CAS Registry111470-99-6
View All Structures (6)

Related

100 Clinical Results associated with Telmisartan/Rosuvastatin Calcium/Amlodipine Besylate/Ezetimibe
Login to view more data
100 Translational Medicine associated with Telmisartan/Rosuvastatin Calcium/Amlodipine Besylate/Ezetimibe
Login to view more data
100 Patents (Medical) associated with Telmisartan/Rosuvastatin Calcium/Amlodipine Besylate/Ezetimibe
Login to view more data
100 Deals associated with Telmisartan/Rosuvastatin Calcium/Amlodipine Besylate/Ezetimibe
Login to view more data

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Dyslipidemias
South Korea
Chong Kun Dang Pharmaceutical Corp.Chong Kun Dang Pharmaceutical Corp.
21 Mar 2025
Essential Hypertension
South Korea
Chong Kun Dang Pharmaceutical Corp.Chong Kun Dang Pharmaceutical Corp.
21 Mar 2025
Hypertension
South Korea
Chong Kun Dang Pharmaceutical Corp.Chong Kun Dang Pharmaceutical Corp.
21 Mar 2025
Primary hypercholesterolemia
South Korea
Chong Kun Dang Pharmaceutical Corp.Chong Kun Dang Pharmaceutical Corp.
21 Mar 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free